secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001654954-23-006560
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences Q1 net loss $2.9M ($0.93/share); cash $2.4M; raised $4.5M in public offering
--------------------------------------------------------------------------------

- Net loss $2.9M ($0.93 per share) in Q1 2023, flat vs $2.9M ($1.33 per share) in Q1 2022.
- Operating expenses $2.9M unchanged YoY; cash and equivalents $2.4M at March 31, 2023.
- Completed data collection for FDA De Novo submission for TAEUS liver fat device; submission planned mid-2023.
- Raised $4.5M net proceeds from public offering subsequent to quarter-end, extending cash runway.
- Added 7 patents year-to-date (3 US, 2 Europe, 2 China); IP portfolio now 63 issued patents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000165495423006560/0001654954-23-006560-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000165495423006560/ndra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-006560

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer